Oncotelic Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $8.66M
- P/E (TTM)
- 0.0
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2021 Ended Sep 30, 2021 | Nov 24, 2021 | After market close | – | – | – |
| Q3 FY2015 Ended Sep 30, 2015 | Nov 10, 2015 | After market close | – | – | – |
| Q2 FY2015 Ended Jun 30, 2015 | Aug 4, 2015 | After market close | – | – | – |
| Q1 FY2015 Ended Mar 31, 2015 | Apr 30, 2015 | After market close | – | – | – |
| Q4 FY2014 Ended Dec 31, 2014 | Mar 17, 2015 | After market close | – | – | – |
| Q3 FY2014 Ended Sep 30, 2014 | Nov 12, 2014 | After market close | – | – | – |
| Q2 FY2014 Ended Jun 30, 2014 | Aug 5, 2014 | After market close | – | – | – |
| Q1 FY2014 Ended Mar 31, 2014 | May 6, 2014 | After market close | – | – | – |
| Q4 FY2013 Ended Dec 31, 2013 | Jan 13, 2014 | During market hours | – | – | – |
| Q3 FY2013 Ended Sep 30, 2013 | Nov 12, 2013 | After market close | – | – | – |
| Q2 FY2013 Ended Jun 30, 2013 | Aug 6, 2013 | After market close | – | – | – |
| Q1 FY2013 Ended Mar 31, 2013 | Apr 9, 2013 | After market close | – | – | – |
Press releases
Announcements Oncotelic Therapeutics filed with the SEC
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress
Other events · EX-99.1 to Form 8-K
Oncotelic Therapeutics Announces Strategic Partnership
Material agreement · Other events · EX-99.1 to Form 8-K
Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026
Other events · EX-99.1 to Form 8-K
Nano to Present Everolimus Toxicology Data at SOT 2026 Annual Meeting
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference
Other events · EX-99.2 to Form 8-K
Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.
Other events · EX-99.1 to Form 8-K
BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem
Regulation FD disclosure · EX-99.1 to Form 8-K
Issues Year End Message to Shareholders
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Presents Clinical Data of Confirming TGF-β2 as the appropriate target for gliomas at JCA-AACR Meeting 2022
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic Cancer
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Update on OT-101 at the 2022 BIO International Convention
Regulation FD disclosure · EX-99.2 to Form 8-K
to Oncotelic Shareholders on the Recently Completed Joint Venture Transaction with Dragon Overseas Capital Limited
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
and Dragon Overseas Capital Limited Completed Joint Venture Transaction
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces positive topline data for OT-101 C001 COVID Study
Regulation FD disclosure · EX-99.1 to Form 8-K
PROVIDES 3 RD QUARTER 2021 COMPARED TO 3 RD QUARTER 2020 FINANCIAL RESULTS AND CORPORATE UPDATE
Results of operations · EX-99.1 to Form 8-K
Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination
Regulation FD disclosure · EX-99.1 to Form 8-K
Acquires FAST TO MARKET LATE-STAGE drug candidate for Parkinson Disease, Erectile Dysfunction, and Female Sexual Dysfunction.
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K